ReviewUrolithiasis2026
Current status of primary hyperoxaluria type 1 in Japan.
Review in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Increased awareness around an ultra-rare disease can improve diagnosis delays: the French example in primary hyperoxalurias.Orphanet journal of rare diseases · 2026Article
- Identification of Primary Hyperoxaluria Type III by Gas Chromatography/Mass Spectrometry-Based Urine Metabolomics.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperoxaluria (PH) is a rare autosomal recessive disorder characterized by an abnormal increase in urinary oxalate excretion. Primary hyperoxaluria type 1 (PH1), the most common PH subtype, is caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase, which is localized to peroxisomes. In Japan, the status of PH1 has not been studied in two decades, and few longitudinal studies of PH1 patients have been conducted worldwide. This study aims to analyze the present situation regarding PH1 in Japan. We conducted a literature review of PH1 cases reported in Japan between 2003 and 2023. Twenty patients were diagnosed with PH1 during the study period, including 7 males, 12 females, and 1 patient with an unspecified sex. The median ages at symptom onset and diagnosis were 4.21 years (range: 0.17-47) and 5.5 years (range: 0.17-43), respectively. Ten patients (50%) were diagnosed before age 18, four (44%) of whom had already progressed to end-stage renal disease (ESRD). Among the six patients diagnosed after 18 years, all had ESRD or progressed to ESRD soon after diagnosis. The overall survival (OS) rate was 81% at 5, 10 and 20 years post-diagnosis. The mean observation period was 5.62 years (range: 0-32.6). Few longitudinal studies on PH1 patients have been conducted in Japan or worldwide. Over the past 20 years, the median ages at both symptom onset and diagnosis have significantly decreased, and the OS rate has increased. Early diagnosis and intervention may contribute to better outcomes for PH1 patients in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.